ORACLE: A Long-term Follow-up Study to Evaluate the Safety and Durability of GT005 in Participants With Geographic Atrophy, Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Latest Information Update: 28 May 2024
At a glance
- Drugs GT 005 (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions
- Acronyms ORACLE
- Sponsors Gyroscope Therapeutics
Most Recent Events
- 02 Nov 2023 Planned number of patients changed from 300 to 225.
- 02 Nov 2023 Planned End Date changed from 16 Sep 2028 to 2 Jun 2028.
- 02 Nov 2023 Planned primary completion date changed from 16 Mar 2028 to 2 Jun 2028.